Oxford Finance LLC
VC Fund
Alexandria, United States
Oxford Finance LLC is a VC fund in Alexandria focused on Biotechnology and Health Care. Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide. Their capital provides clients with the fuel needed for innovation and growth.
- Total investments:
- 125
- Last investment:
- Lead investor:
- 51%
Last updated:
For AI agents: llms.txt
Industries Oxford Finance LLC invests in
Stages Oxford Finance LLC invests in
Countries Oxford Finance LLC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $39M–$76M
- Post-IPO Debt
- $15M–$150M
- Debt Financing
- $7.5M–$96M
Investment Focus
Industry
- Biotechnology 82 (66%)
- Health Care 75 (60%)
- Medical 33 (26%)
- Medical Device 31 (25%)
- Pharmaceutical 30 (24%)
Stage
- Debt Financing 62 (50%)
- Post-IPO Debt 47 (38%)
- Series B 2 (2%)
- Funding Round 2 (2%)
- Post-IPO Equity 2 (2%)
Country
- United States 103 (82%)
- United Kingdom 6 (5%)
- Canada 2 (2%)
- Ireland 2 (2%)
- Germany 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam K. Soller
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Christopher A. Herr
Senior Managing Director
|
Senior Managing Director | Total investments: 22 | Find email | |
Colette Hastings Featherly
Vice President, Corporate Finance
|
Vice President, Corporate Finance | Total investments: 0 | Find email | |
Darren J. Margulis
Senior Director, Credit & Portfolio Management
|
Senior Director, Credit & Portfolio Management | Total investments: 0 | Find email | |
J. Alden Philbrick
President & Chief Executive Officer
|
President & Chief Executive Officer | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inhibrx
|
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology,orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X. | $100M / Post-IPO Debt / Jul 16, 2026 | |
Vortexa
|
Vortexa provides a real-time data and analytics platform for energy and freight industries. The company covers all vessel classes of crude oil, refined products, LPG, and LNG. It helps traders, analysts, and freight professionals gain a competitive edge in complex and opaque markets by confidently making trading decisions. Its platform usesartificial intelligence to analyze and interpret data and absorb data points from multiple sources to show oil's past, present, and future flow worldwide. | $50M / Debt Financing / Apr 14, 2026 | |
|
Inhibrx
|
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology,orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X. | $75M / Post-IPO Debt / Mar 18, 2026 | |
Sokin
|
Sokin is a leading financial service provider that enables global payments for both consumers and businesses. Sokin believes in giving you the power to make payments and transfer money as many times as you want per month! Whether it’s sending money back home or transfers to friends or even settling with businesses using Sokin, our innovativeprocess makes the task quick and easy.Sokin delivers global payments for a fixed fee, is commission and hassle free!Transferring money internationally is complicated and expensive. Sometimes there is a lack of transparency in the fees you pay. With our transparent fixed monthly costs, for businesses and consumers, there are no hidden charges. You will not have to spend hours researching the best rates!Our cost effective solution is simple to understand: One Monthly Fee. This will to allow you to make payments in over 200 countries and the ability to exchange money in over 150 countries in over 35 different currencies. Sokin can also transfer any currency into any bank account in China within 2 hours excluding weekends and Chinese bank holidays.To find out more about the only payment provider to provide global payments for a fixed fee, commission free and hassle free – download our app and sign up to ensure you don’t miss out on key messages! | $96.4M / Debt Financing / Jan 28, 2026 | |
Quality Life Science Logistics & Transportation
|
Quality Life Science Logistics & Transportation specializes in cold chain transportation and freight services for pharmaceutical companies. | Private Equity / Dec 02, 2025 | |
Kyverna Therapeutics
|
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. | $25M / Post-IPO Debt / Nov 03, 2025 | |
Celcuity
|
Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving apatient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. | $500M / Post-IPO Debt / Sep 09, 2025 | |
Vera Therapeutics
|
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential. The company's gene-editing technology can potentially cure patients with sickle cell disease, cystic fibrosis, and other devastating genetic disorders, enabling physicians to improve gene detection and regulation. | $75M / Post-IPO Debt / Jun 03, 2025 | |
|
Inhibrx
|
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology,orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X. | $150M / Post-IPO Debt / Jan 13, 2025 | |
Soleno Therapeutics
|
Soleno Therapeutics is a clinical-stage biopharmaceutical company. | $50M / Post-IPO Debt / Dec 17, 2024 | |
| See all 125 investments → | |||
Co-Investors
Silicon Valley Bank
26 deals together
Square 1 Bank
4 deals together
East West Bank
3 deals together
MidCap Financial
3 deals together
Armentum Partners
2 deals together
AB Private Credit Investors
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Oxford Finance LLC invest in?
Oxford Finance LLC invests primarily in Biotechnology, Health Care and Medical startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 125 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Oxford Finance LLC's check size?
Oxford Finance LLC typically joins rounds of $39M–$76M at Series B, $15M–$150M at Post-IPO Debt and $7.5M–$96M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Oxford Finance LLC participates in.
How do I contact Oxford Finance LLC?
Public channels for Oxford Finance LLC include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oxford Finance LLC?
The team at Oxford Finance LLC includes Adam K. Soller (Managing Director), Christopher A. Herr (Senior Managing Director) and Colette Hastings Featherly (Vice President, Corporate Finance), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
